Covance cutting 200 workers; Celgene names Hugin CEO; pSivida gains $15M from Alimera;

 @FierceBiotech: E&Y: A resilient biotech industry registers its first profitable year. Article | Follow @FierceBiotech 

 @JohnCFierce: Pfizer developing "bio-betters," seeking rare blood disorder drugs. Article | Follow @JohnCFierce

> Covance says it will cut some 200 jobs at it closes two of its trial sites. The CRO also lowered its full-year outlook, citing delays in late-stage testing. Story

> Celgene is promoting COO Robert Hugin to the CEO post. Celgene release

> If Generex thought that filing a lawsuit against TheStreet and Adam Feuerstein for their coverage of the company would put a chill on the aggressive biotech reporter, they were wrong. Today Feuerstein put Generex back at the whipping post, caustically criticizing the small developer for its claims regarding the FDA's position on its therapy Oral-lyn. Report

> Watertown, MA-based pSivida has garnered a $15 million milestone from Alimera Sciences. And it stands to earn another $25 million the diabetic macular edema drug Iluvien is approved by the FDA. Story

> Pozen reported a $3 million quarterly loss as it waits for a final decision from the FDA on the arthritis drug Vimovo. An approval would trigger a $20 million milestone from AstraZeneca, which licensed the drug. Report

> Shares of Novavax were buoyed slightly by the news that its mid-stage trial of a closely watched seasonal flu vaccine demonstrated significant immunogenicity against one of three flu strains among elderly patients with its higher dose. Story

> Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a €4 million ($5.5 million) investment from HealthCap. Oncos release

> AVI BioPharma gained an extra $4 million from the U.S. Defense Threat Reduction Agency to fund preclinical work on its H1N1 drug candidate. AVI release

And Finally... Researchers say that Canada's universal healthcare system may be one big reason why Canadians live three years longer than Americans on average, with far fewer health problems. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.